Clinical effect of Kunxian Capsules combined with Valsartan in the treatment of diabetic nephropathy stage Ⅳ proteinuria
WANG Huimin1 WU Yiwei2 CHEN Zhixian3
1.Department of Nephropathy, Tangshan Hospital of Traditional Chinese Medicine, Hebei Province, Tangshan 063000, China;
2.Department of General Surgery, Tangshan Hospital of Traditional Chinese Medicine, Hebei Province, Tangshan 063000, China;
3.School of Medicine, Ji′nan University, Guangdong Province, Guangzhou 510630, China
Abstract：Objective To explore the clinical effect of Kunxian Capsules combined with Valsartan in the treatment of diabetic nephropathy stage Ⅳ proteinuria. Methods Sixty-one patients with diabetic nephropathy stage Ⅳ admitted to Tangshan Hospital of Traditional Chinese Medicine, Hebei Province from January 2018 to January 2019 were selected. According to the random number table method, they were divided into the control group and the observation group. Thirty patients in the control group were treated with Valsartan, and thirty-one patients in the observation group were treated with Kunxian Capsules on the basis of the control group. The treatment course of the two groups was 3 months. The changes of quantitative comparison of 24-hour urinary protein , renal function index(blood urea nitrogen [BUN], serum creatinine [Scr], endogenous creatinine clearance rate [Ccr]), liver function index (plasma albumin [Alb], alanine aminotransferase [ALT], aspartate aminotransferase [AST]) and peripheral blood leukocyte (WBC) of the two groups before and after treatment were observed and the adverse reactions were monitored. Results Before treatment, the quantitative comparison of 24-hour urinary protein between the two groups was not statistically significant difference (P ＞ 0.05). After treatment, the quantitative comparison of 24-hour urinary protein in both groups was lower than that before treatment, and the observation group was lower than the control group, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). There were no statistically significant differences in BUN, Scr, Ccr, Alb, ALT, AST and WBC levels between the two groups before and after treatment (P ＞ 0.05). No serious side effects were found that required drug withdrawal. Conclusion Kunxian Capsules combined with Valsartan is effective in the treatment of diabetic nephropathy stage Ⅳ, which can effectively reduce the level of patients with diabetic nephropathy proteinuria, so as to better protect renal function, and its safety is good, worthy of clinical promotion and application.
2020, Vol. 17 
京公网安备 11010502046598号